Relief Therapeutics and NeuroX to Merge, Expanding AI Health Tech

Relief Therapeutics Holding SA announced a proposed merger with NeuroX Group SA, which recently acquired MindMaze's operations. This merger aims to form an AI-driven health tech company, enhancing capabilities in treating neurological diseases. NeuroX brings to the table a portfolio backed by clinical validation and partnerships with pharmaceutical companies.

The merger is set to create a publicly listed entity on the SIX Swiss Exchange, integrating digital neurotherapeutics with pharmacological treatments through an AI platform. This strategic move is expected to enhance global market presence and innovation in neurology treatment solutions.

Relief's board chairman, Dr. Raghuram Selvaraju, expressed confidence in creating value for patients and shareholders alike. As stakeholders negotiate final terms, the merger seeks to leverage MindMaze's technologies for a broader impact in the medical field. If approved, the transaction is expected to close by Q4 2025.